Hepatitis C virus driven AXL expression suppresses the hepatic type i interferon response

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Read, Scott A ^a   Tay, Enoch S ^a   Shahidi, Mahsa ^a   O'Connor, Kate S ^a   Booth, David R ^a   George, Jacob ^a   Douglas, Mark W ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON STIMULATED GENE FACTOR 15; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; AXL GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE INDUCTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IFNL3 GENE; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRAL CLEARANCE; BIOSYNTHESIS; CHRONIC HEPATITIS C; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HEPACIVIRUS; LIVER; MALE; METABOLISM; PATHOLOGY;

FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER; MALE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84943253490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136227     Document Type: Article

References (42)

1. Horner SM, Gale M Jr (2013) Regulation of hepatic innate immunity by hepatitis C virus. Nature Medicine 19: 879-888. doi: 10.1038/nm.3253 PMID: 23836238
2. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM (2007) Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46: 999-1008. PMID: 17668868
3. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039. doi: 10.1073/pnas.0707882105 PMID: 18467494
4. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al. (2009) Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29: 4841-4851. doi: 10.1128/MCB.00224-09 PMID: 19564419
5. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH (2004) Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126: 263-277. PMID: 14699505
6. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. (2003) IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17: 488-490. PMID: 12551851
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104. doi: 10.1038/ng.447 PMID: 19749758
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109. doi: 10.1038/ng.449 PMID: 19749757
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401. doi: 10.1038/nature08309 PMID: 19684573
10. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics 45: 164-171. doi: 10.1038/ng.2521 PMID: 23291588
11. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, et al. (2006) Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 203: 1891-1901. PMID: 16831897
12. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131: 1124-1136. PMID: 18083102
13. Read SA, Tay ES, Shahidi M, McLauchlan J, George J, Douglas MW (2015) The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor alpha Agonist. Journal of Interferon and Cytokine Research.
14. O'Connor KS, Parnell G, Patrick E, Ahlenstiel G, Suppiah V, van der Poorten D, et al. (2014) Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes Immun 15: 88-94. doi: 10.1038/gene.2013.66 PMID: 24335707
15. Read SA, Tay E, Shahidi M, George J, DouglasMW(2014) Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology 95: 1900-1910. doi: 10.1099/vir.0.065300-0 PMID: 24859394
16. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006. PMID: 12045153
17. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L (2004) ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res 32: W280-286. PMID: 15215395
18. Loots GG, Ovcharenko I (2004) rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 32: W217-221. PMID: 15215384
19. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. (2003) Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125: 1808-1817. PMID: 14724833
20. Zheng S, Hedl M, Abraham C (2015) TAM Receptor-Dependent Regulation of SOCS3 and MAPKs Contributes to Proinflammatory Cytokine Downregulation following Chronic NOD2 Stimulation of Human Macrophages. J Immunol 194: 1928-1937. doi: 10.4049/jimmunol.1401933 PMID: 25567680
21. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, et al. (2014) Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15: 190-202. doi: 10.1016/j.chom.2014.01.007 PMID: 24528865
22. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. (2007) Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46: 1009-1015. PMID: 17668875
23. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. (2007) Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132: 733-744. PMID: 17258724
24. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125: 1695-1704. PMID: 14724822
25. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. (2007) The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45: 1164-1171. PMID: 17465001
26. Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, et al. (2009) Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol 183: 3004-3013. doi: 10.4049/jimmunol.0804384 PMID: 19657094
27. Yie J, Senger K, Thanos D (1999) Mechanism by which the IFN-beta enhanceosome activates transcription. Proceedings of the National Academy of Sciences of the United States of America 96: 13108-13113. PMID: 10557281
28. You LR, Chen CM, Lee YH (1999) Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. J Virol 73: 1672-1681. PMID: 9882379
29. Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, et al. (2010) Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 138: 2509-2518, 2518 e2501. doi: 10.1053/j. gastro.2010.03.008 PMID: 20230822
30. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, et al. (2004) Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J 378: 919-928. PMID: 14670077
31. Soo HM, Garzino-Demo A, Hong W, Tan YH, Tan YJ, Goh PY, et al. (2002) Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 303: 253-277. PMID: 12490388
32. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. (2012) HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142: 978-988. doi: 10.1053/j.gastro.2011.12.055 PMID: 22248663
33. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, et al. (2012) IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56: 2060-2070. doi: 10.1002/hep.25897 PMID: 22706965
34. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896. doi: 10.1002/hep.23912 PMID: 20931559
35. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509. doi: 10.1053/j.gastro.2010.04.049 PMID: 20434452
36. Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, et al. (1998) Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 50: 331-340. PMID: 9676427
37. He L, Zhang J, Jiang L, Jin C, Zhao Y, Yang G, et al. (2010) Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog 49: 882-891. doi: 10. 1002/mc.20664 PMID: 20635370
38. Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH (2014) Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 35: 769-775. doi: 10.1093/carcin/bgt372 PMID: 24233839
39. Linger RM, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83. doi: 10. 1016/S0065-230X(08)00002-X PMID: 18620092
40. Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, McCray PB Jr., et al. (2011) Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology 415: 83-94. doi: 10.1016/j.virol.2011.04.002 PMID: 21529875
41. Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, Wu AM, et al. (2011) The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9: 286-298. doi: 10.1016/j.chom.2011.03.012 PMID: 21501828
42. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, et al. (2012) The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12: 544-557. doi: 10.1016/j.chom.2012.08.009 PMID: 23084921